EC Microbiology

Introduction: The impact of diabetes on quality of life and health care costs is affected by numerous factors in addition to diabetes-associated complications. Microvascular, macrovascular and distal symmetric polyneuropathy (DSPN) are the most common neurologic complication and a major cause of morbidity in diabetic patients.

Aim of the Work: Minimizing the risk, prevention, and management of long-term complications of diabetes mellitus will be addressed in this review.

Methods: This article is a non-systematic, non-analytic literature review of medical literature.

Conclusion: Ongoing evaluation should include history taking and physical examination 2 - 4 times per year. Hypertension, hypercholesterolemia, smoking and 75 - 162 daily aspirin are recommended in patients with, or at high risk for ASCVD.

Bariatric surgery can reduce neuropathy incidence and lifestyle interventions are essential to prevent onset and slow progression of neuropathy. Duloxetine, venlafaxine, amitriptyline, pregabalin and gabapentin are the first-line agents for pain management.

Keywords: Diabetes Mellitus; Chronic Complications; Risks; Management

1. Diabetes Data and Statistics.
2. Dieleman JL., et al. “US Spending on Personal Health Care and Public Health, 1996-2013”. The Journal of the American Medical Association 316 (2016): 2627.
3. Kan C., et al. “A systematic review and meta-analysis of the association between depression and insulin resistance”. Diabetes Care 36 (2013): 480.
4. American Diabetes Association. “Economic Costs of Diabetes in the U.S. in 2017”. Diabetes Care 41 (2018): 917.
5. Diabetes Control and Complications Trial Research Group Nathan DM., et al. “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus”. The New England Journal of Medicine (1993).
6. Nathan DM., et al. “Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes”. The New England Journal of Medicine 353 (2005): 2643.
7. Harris MI., et al. “Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis”. Diabetes Care 15 (1992): 815.
8. Gregg EW., et al. “Changes in diabetes-related complications in the United States, 1990-2010”. The New England Journal of Medicine 370 (2014): 1514.
9. Kennon B., et al. “Reduced incidence of lower-extremity amputations in people with diabetes in Scotland: a nationwide study”. Diabetes Care 35 (2012): 2588.
10. Willis JR., et al. “Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States”. JAMA Ophthalmology 135 (2017): 926.
11. American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020”. Diabetes Care 43 (2020): S135.
12. Mogensen CE., et al. “Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion”. Diabetes Care 18 (1995): 572.
13. Qaseem A., et al. “Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians”. Annals of Internal Medicine 159 (2013): 835.
14. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020”. Diabetes Care 43 (2020): S111.
15. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020”. Diabetes Care 43 (2020): S66.
16. Wei N., et al. “Empirically establishing blood glucose targets to achieve HbA1c goals”. Diabetes Care 37 (2014): 1048.
17. Seshasai SR., et al. “Diabetes mellitus, fasting glucose, and risk of cause-specific death”. The New England Journal of Medicine 364 (2011): 829.
18. Fan AZ., et al. “Trends in cigarette smoking rates and quit attempts among adults with and without diagnosed diabetes, United States, 2001-2010”. Preventing Chronic Disease 10 (2013): E160.
19. Yudkin JS. “How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects”. British Medical Journal 306 (1993): 1313.
20. ASCEND Study Collaborative Group, Bowman L, et al. “Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus”. The New England Journal of Medicine 379 (2018): 1529.
21. Antithrombotic Trialists’ Collaboration. “Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients”. British Medical Journal 324 (2002): 71.
22. Kunutsor SK., et al. “Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials”. Diabetic Medicine 34 (2017): 316.
23. Ikeda Y., et al. “Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial”. The Journal of the American Medical Association 312 (2014): 2510.
24. Chew EY., et al. “Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20”. Archives of Ophthalmology 113 (1995): 52.
25. Whelton PK., et al. “ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American (2017).
26. Pop-Busui R., et al. “Diabetic Neuropathy: A Position Statement by the American Diabetes Association”. Diabetes Care 40 (2017): 136.
27. Callaghan BC., et al. “Enhanced glucose control for preventing and treating diabetic neuropathy”. Cochrane Database of Systematic Reviews (2012): CD007543.
28. Cortez M., et al. “Glucose intolerance, metabolic syndrome, and neuropathy”. The Handbook of Clinical Neurology 126 (2014): 109.
29. Müller-Stich BP., et al. “Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization--results of a prospective cohort study (DiaSurg 1 study)”. Annals of Surgery 258 (2013): 760.
30. Davies M., et al. “The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes”. Diabetes Care 29 (2006): 1518.
31. Young RJ., et al. “Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology”. Diabetes Care 11 (1988): 34.
32. Griebeler ML., et al. “Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis”. Annals of Internal Medicine 161 (2014): 639.